The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Findings of an MAIC comparing epcoritamab and mosunetuzumab for R/R FL
In this video, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, outlines the findings of a matching-adjusted indirect comparison (MAIC) of the bispecific antibodies epcoritamab and mosunetuzumab in relapsed/refractory (R/R) follicular lymphoma (FL), highlighting the differences in their safety and efficacy. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Bispecific antibodies are coming fast and furious in the treatment of hematologic malignancies and actually solid tumors as well, but they certainly have made a very big impact already in therapy of lymphoid malignancies. Epcoritamab and mosunetuzumab have been approved in therapy of relapsed/refractory follicular lymphoma and both agents show very high efficacy. So there are certainly no randomized trials which compare those two approved agents to each other...
Bispecific antibodies are coming fast and furious in the treatment of hematologic malignancies and actually solid tumors as well, but they certainly have made a very big impact already in therapy of lymphoid malignancies. Epcoritamab and mosunetuzumab have been approved in therapy of relapsed/refractory follicular lymphoma and both agents show very high efficacy. So there are certainly no randomized trials which compare those two approved agents to each other. And therefore we conducted a MAIC analysis using clinical trial data from both of these drugs.
So what we have found is that epcoritamab induced numerically higher overall response rate compared to mosunetuzumab. And additionally, we found that epcoritamab had no grade 3 toxicities such as CRS and ICANS in follicular lymphoma patients. Whereas with mosunetuzumab, we saw a few of these toxicities, although they were very infrequent.
In general, progression-free survival on these drugs was very similar. So both are very good agents in therapy of follicular lymphoma. Currently, epcoritamab is approved as a subcutaneous formulation, which may make it a very attractive agent for using in patients with follicular lymphoma as well. But nevertheless, it is great to have those two exciting options for these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
